Figure 3
Figure 3. Characterization of the TIE2+ monocytes. (A) TIE2+ cells in unfractioned PBMCs were gated and analyzed for the expression of a panel of hematopoietic markers, as indicated in the histogram plots. The red open line shows expression of the indicated marker in the gated TIE2+ population (with the percentage of marker-positive cells in red); the filled line depicts expression of the indicated marker in the TIE2− cell population (with the percentage of marker-positive cells in black). The TIE2+ cells were CD45+, CD11b+, CD11c+, CD16+, CD33+, CD115+, and CD13+, which are all markers of monocytic cells. In addition, the TIE2+ cells were CCR2−, CD62L (L-selectin)−, and CCR5+, a surface profile previously associated with resident monocytes. As expected, the TIE2+ cells were CD56−, CD3−, and CD19− and thus distinct from natural killer cells and T and B lymphocytes. Representative analysis of 3 to 6 experiments performed on different donors.

Characterization of the TIE2+ monocytes. (A) TIE2+ cells in unfractioned PBMCs were gated and analyzed for the expression of a panel of hematopoietic markers, as indicated in the histogram plots. The red open line shows expression of the indicated marker in the gated TIE2+ population (with the percentage of marker-positive cells in red); the filled line depicts expression of the indicated marker in the TIE2 cell population (with the percentage of marker-positive cells in black). The TIE2+ cells were CD45+, CD11b+, CD11c+, CD16+, CD33+, CD115+, and CD13+, which are all markers of monocytic cells. In addition, the TIE2+ cells were CCR2, CD62L (L-selectin), and CCR5+, a surface profile previously associated with resident monocytes. As expected, the TIE2+ cells were CD56, CD3, and CD19 and thus distinct from natural killer cells and T and B lymphocytes. Representative analysis of 3 to 6 experiments performed on different donors.

Close Modal

or Create an Account

Close Modal
Close Modal